When standard cartilage repair is not enough

Some knee injuries do more than scratch the surface. When a high-energy impact or intra-articular fracture tears through the articular cartilage and into the subchondral bone beneath it, the resulting defect is composite — two tissue layers gone, not one. That combination is the reason patients are sometimes told that standard cartilage repair will not work for them.

The difficulty starts with biology. Articular cartilage has no blood supply and essentially no capacity to repair itself. When damage is confined to the cartilage surface and the defect is small — typically under 2 cm² — techniques such as microfracture or an osteochondral autograft transfer (OATS) can work well. Once a post-traumatic defect exceeds roughly 2–4 cm², however, those options run out of biological and geometric runway. Cell-based procedures such as MACI restore the cartilage layer but do not address loss of the subchondral bone beneath it — a critical gap in any injury where the bone itself has been disrupted.

Osteochondritis dissecans (OCD) is a common reason athletes reach this threshold; high-energy post-traumatic injury is the other major pathway. For patients in either group whose defect is large, full-thickness, and extends into bone, fresh osteochondral allograft (OCA) transplantation becomes the appropriate next conversation — and the focus of this article.

What OCA transplantation actually involves

Tissue for OCA transplantation comes from a specialist tissue bank — a donor who has passed rigorous screening. The graft consists of articular cartilage bonded to its own underlying bone, cut and shaped to match the size and curvature of the patient's defect as closely as possible. Across published series, the medial femoral condyle — the inner rounded end of the thigh bone — is the most frequently treated site.

The word fresh matters here. Unlike many transplanted tissues, OCA cannot be frozen: freezing destroys most of the chondrocytes, the living cells that maintain cartilage over the long term. The graft is instead kept refrigerated in cold saline and must be implanted within a defined window after procurement. How the tissue is handled at the point of harvest also affects cell survival — research published in 2025 found that cold saline submersion during reaming maintained chondrocyte viability at approximately 75%, compared with roughly 59% when harvesting was done dry. That difference in starting quality has practical consequences for how well the graft integrates once transplanted.

For patients, the most immediately relevant point is that OCA is a single-stage operation. Unlike ACI or MACI — which require an initial biopsy, a laboratory culture period of several weeks, and then a second procedure — OCA needs one visit to the operating theatre. The donor tissue arrives matched and ready; there is no waiting for cells to be grown outside the body.

Who is a suitable candidate

Broadly speaking, OCA suits younger, active patients — typically under 40 to 50 years of age — who have a large, focal defect confined to one side of the joint (termed unipolar) and otherwise healthy surrounding cartilage. That profile captures most post-traumatic presentations: a single, well-demarcated area of damage arising from a fracture or high-energy impact, in a knee that was structurally sound before the injury.

Mechanical prerequisites matter as much as the defect itself. The knee must be ligament-stable, or stability must be restored at the time of surgery — an OCA graft placed into an unstable joint is subject to abnormal loading that compromises integration. Similarly, any significant varus or valgus malalignment must be correctable, either concurrently with an osteotomy or as a staged procedure; allowing the graft to bear asymmetric load is a recognised risk factor for failure.

Some situations represent clear contraindications. Diffuse osteoarthritis, in which cartilage loss is widespread rather than focal, places OCA outside its design envelope — those patients are better served by a joint-preservation or replacement conversation. Uncorrected malalignment is an absolute contraindication for the same mechanical reasons. Bipolar, or 'kissing', lesions — where both the femoral and tibial surfaces are damaged — carry meaningfully lower survival rates than unipolar cases, and published series confirm a substantially higher reoperation risk; the detailed figures are explored in the next section.

For post-pubertal children and adolescents, the evidence is encouraging: OCA shows the lowest failure rate of all surgical cartilage techniques in that age group, and the procedure is not limited to adults.

In England, NHS England commissioned OCA as a Group D specialised service from October 2022, meaning eligible patients can access the procedure without an individual funding request — a practical point for anyone weighing NHS versus private routes.

Survivorship and long-term outcomes

Graft survival figures for primary, unipolar OCA are robust across multiple published cohorts. At five years, survival sits at approximately 85–90%; at ten years, roughly 75–80%. One long-term post-traumatic series found 68% of grafts still functioning and in situ at a mean follow-up of 12.9 years — a meaningful benchmark for patients facing this operation in their thirties or forties.

The picture changes substantially when both surfaces of a compartment are involved. For bipolar OCA — where femoral and tibial lesions are treated simultaneously — published survivorship drops to 73.8% at five years and 58.9% at fifteen years. In one series of 89 knees with a mean treated surface area of 16.7 cm², graft failure occurred in 34.8% of cases and reoperations in over half. These figures are not a reason to exclude carefully selected patients from treatment, but they underscore why the unipolar versus bipolar distinction is one of the strongest determinants of prognosis — and why clinicians weight it heavily at the candidacy stage.

When OCA follows prior cartilage surgery

Used as a salvage procedure after failed marrow stimulation or other cartilage repair, OCA still achieves five-year survival of 79–87.8%, falling to 61–82% at ten years. The trade-off is a reoperation rate of 42.8% — notably higher than in primary cases. Defect size drives much of that risk: lesions reaching 9–10 cm² carry a 39% failure rate and a 67% reoperation rate, making defect area the single most important modifiable variable when planning intervention.

Return to sport and functional recovery

Recovery from OCA is measured in months rather than weeks — a timeline that distinguishes it from simpler procedures such as microfracture and should be set as a clear expectation before surgery.

The evidence on functional outcomes is, however, reassuring. At mean six-year follow-up, 75.2% of 149 knees had returned to sport or recreational activity, with 71% achieving very good or excellent IKDC knee function scores. In athlete-specific cohorts, the return-to-sport rate was 72% — and of those who returned, 84% did so at the same or higher level of participation, at a weighted mean of 11.1 months post-surgery.

Biomechanical recovery follows a similar trajectory. Post-operative knee range of motion consistently exceeds 120° across published studies and is statistically comparable to ACI — a useful benchmark given ACI's own strong functional track record.

One emerging adjunct merits attention. A 2025 prospective randomised trial (n=36) found that adding bone marrow aspirate concentrate (BMAC) at the time of OCA reduced the reoperation rate from 35.3% to 5.3%. The effect on patient-reported outcomes was not significant at up to two years, and the sample size means it has not yet changed standard practice — but the finding is being watched as a possible route to reducing the reoperation burden seen in complex and larger-defect cases.

Risk factors, evidence gaps, and next steps

Several factors consistently predict a worse outcome after OCA, and a thorough pre-operative assessment is designed to surface them. Older patient age, higher BMI, tobacco use, bipolar lesion configuration, concurrent ligament reconstruction, and a history of prior failed cartilage surgery all carry independently elevated failure risk across published cohorts. These variables rarely travel alone: larger, more anatomically complex reconstructions tend to compound multiple risk vectors simultaneously.

Donor-recipient sex mismatch does not affect overall graft survivorship — in a 285-patient series, the difference between sex-matched and sex-mismatched groups was not statistically significant (p=0.70). That said, when sex-mismatched grafts did fail, they did so earlier: a median of 353 days compared with 864 days in matched pairs. The finding may reflect immunological acceleration of early failure rather than a categorical incompatibility, and its clinical implications are still being characterised.

Several important questions remain open. Long-term data beyond fifteen years for high-chondrocyte-viability protocols are not yet available. Biomechanical evidence is thin — one systematic review drew on only 54 participants across eight studies. And head-to-head comparisons between OCA and MACI specifically for post-traumatic defects — where the subchondral bone lesion is often the central problem — have not yet been conducted. That last gap is practically significant: it means the choice between the two strategies still rests largely on anatomy, lesion depth, and clinical judgement rather than comparative trial data.

What this evidence collectively suggests is that OCA is best understood as one component of a structured plan rather than a self-contained procedure. Alignment correction (HTO or DFO), ligament reconstruction, and biologic adjuncts may be required before, alongside, or after the graft — and the sequencing matters as much as the technique itself. For patients weighing this option, the starting point is a candidacy assessment that reviews imaging, alignment, and realistic timelines before any surgical commitment is made.

1. [1] Treatment options and outcomes for paediatric knee cartilage lesions: a systematic review. (2025). https://doi.org/10.1016/j.knee.2025.08.020 https://doi.org/10.1016/j.knee.2025.08.020
2. [2] Osteochondral Allograft Transplantation as a Salvage Procedure After Failed Index Cartilage Surgery of the Knee: A Systematic Review. (2025). https://doi.org/10.1177/03635465241238466 https://doi.org/10.1177/03635465241238466
3. [3] Midterm Survivorship and Clinical Outcomes in Fresh Osteochondral Allograft Transplantation for Large Bipolar Lesions of the Knee. (2025). https://doi.org/10.1177/03635465241313139 https://doi.org/10.1177/03635465241313139
4. [4] Mid-term failure rates, timing, and mechanisms for osteochondral allograft transplantation in the knee. (2025). https://doi.org/10.1016/j.jor.2025.03.040 https://doi.org/10.1016/j.jor.2025.03.040
5. [5] Midterm Outcomes After Osteochondral Allograft Transplantation in the Knee Using High–Chondrocyte Viability Grafts. (2024). https://doi.org/10.1177/03635465241285457 https://doi.org/10.1177/03635465241285457
6. [6] High-Chondrocyte-Viability OCA Transplantation in the Knee for Revision of Failed Cartilage Repair Procedures. (2025). https://doi.org/10.1055/a-2710-6069 https://doi.org/10.1055/a-2710-6069
7. [7] Donor-recipient sex mismatch does not affect graft survivorship after knee osteochondral allograft transplantation. (2025). https://doi.org/10.1016/j.knee.2025.05.029 https://doi.org/10.1016/j.knee.2025.05.029
8. [8] The biomechanical and functional outcomes of fresh osteochondral allograft for the knee: A systematic review. (2025). https://doi.org/10.1016/j.jcot.2025.102983 https://doi.org/10.1016/j.jcot.2025.102983